Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel Therapeutics for Treating Opioid Use Disorder

Award Number: F31DA060668
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 06/10/2025
PERIOD OF PERFORMANCE END DATE: 06/09/2027

Group Awards By:

View Award Description

Novel Therapeutics for Treating Opioid Use Disorder - PROJECT SUMMARY Opioid Use Disorder (OUD) is a prevalent issue in the United States, characterized by the chronic misuse of opioids, resulting in severe consequences such as fatal overdoses, infectious diseases, increased crime rates, and socioeconomic burdens. Despite the availability of treatment options, OUD remains a significant global challenge. The current FDA-approved therapies for OUD include methadone, buprenorphine, and naltrexone. However, these treatments have limitations, including failure to treat all OUD patients, frequent clinic visits, and low retention rates. To address these challenges, this project aims to develop and explore alternative approaches fordrug delivery that can optimize therapeutic outcomes for individuals with OUD. Specifically, this proposal investigates the therapeutic potential of Nor-Levo-α-acetylmethadol (nor-LAAM). Nor-LAAM is an active metabolite of Levo-α-acetylmethadol (LAAM), an FDA-approved drug to treat OUD. LAAM is a high- efficacy agonist at Mu Opioid Receptors (MOR) and was administered orally three times a week, showing promising results in reducing opioid-positive urine tests, incarceration rates, and prolonged abstinence. However, it was reported that LAAM is associated with cardiovascular risks, specifically QT prolongation and torsades de pointes (TdP). Previous studies have shown that QT prolongation is primarily attributed to the parent drug LAAM itself rather than its metabolite nor-LAAM, as nor-LAAM exhibits a higher IC50 of 12 μM to inhibit HERG potassium channels compared to 3 μM of LAAM. Additionally, nor-LAAM is more potent at MOR than LAAM. This proposal involves utilizing biodegradable polymers to develop nor-LAAM-loaded polymeric microparticles (Nor-LAAM-MP) with in vitro sustained release capabilities (≥1 month) suitable for subcutaneous administration to treat OUD. We hypothesize that these microparticles will enable a controlled release of nor-LAAM, thereby reducing dosing frequency and drug dose and enhancing patient adherence while mitigating the risk of drug-related adverse effects and potential toxicities. We plan to conduct pharmacokinetics, efficacy, and safety studies. By completing this project, we can enhance our understanding of the therapeutic potential and safety profiles associated with nor-LAAM-MP for treating opioid use disorder.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $50,114 )
2026	2026	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Drug Use and Addiction Research Programs	000	2	5/25/2026	NON-COMPETING CONTINUATION	$50,114
														Subtotal = $50,114

Issue Date FY: 2025 ( Subtotal = $48,974 )
2025	2025	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Drug Use and Addiction Research Programs	001	1	12/10/2024	NEW	$0
2025	2025	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Drug Use and Addiction Research Programs	000	1	12/10/2024	NEW	$48,974
														Subtotal = $48,974

Grand Total All Awards = $99,088

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel Therapeutics for Treating Opioid Use Disorder

Award Number: F31DA060668

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 06/10/2025

PERIOD OF PERFORMANCE END DATE: 06/09/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer